Skip to main content
Top
Published in: Health Care Analysis 2/2011

01-06-2011 | Original Article

Should Non-Invasiveness Change Informed Consent Procedures for Prenatal Diagnosis?

Authors: Zuzana Deans, Ainsley J. Newson

Published in: Health Care Analysis | Issue 2/2011

Login to get access

Abstract

Empirical evidence suggests that some health professionals believe consent procedures for the emerging technology of non-invasive prenatal diagnosis (NIPD) should become less rigorous than those currently used for invasive prenatal testing. In this paper, we consider the importance of informed consent and informed choice procedures for protecting autonomy in those prenatal tests which will give rise to a definitive result. We consider whether there is anything special about NIPD that could sanction a change to consent procedures for prenatal diagnosis or otherwise render informed decision-making less important. We accept the claim that the absence of risk of miscarriage to some extent lessens the gravity of the decision to test compared with invasive methods of testing. However, we also claim that the definitive nature of the information received, and the fact that the information can lead to decisions of great significance, makes NIPD an important choice. This choice should only be made by means of a rigorous and appropriately supported decision-making process (assuming that this is what the pregnant woman wants). We conclude that, on balance, consent procedures for NIPD should mirror those for invasive testing, albeit without the need to emphasise procedure-related risk.
Footnotes
1
As ffDNA is derived from the placenta, there is a small chance that the genetic information in the maternal bloodstream may not be exactly representative of the fetus.
 
2
We recognise that the ‘routinisation’ of screening and testing in pregnancy is ethically contentious and has been debated in the ethics literature [5]. However, a substantive consideration of the nuances of the debate over routinisation is beyond the central scope of this paper.
 
3
For example, a measure of the thickness of the nuchal fold (the thickness on the back of the fetus’ neck) that lies on the 99th percentile of the normal distribution may have no clinical significance, but it may also indicate a risk of Down Syndrome.
 
4
Policy on how NIPD is to be offered to pregnant women is not yet determined and is the subject of an ongoing UK national research programme (http://​www.​rapid.​nhs.​uk). NIPD could be offered to (1) replace antenatal screening programmes with a ‘one stop’ definitive indication of risk; (2) as an intermediary step between antenatal screening and invasive diagnosis; or (3) as a follow-up to antenatal screening instead of invasive prenatal diagnosis; in the same way that amniocentesis is offered now. Which of (1)–(3) is chosen will depend on the success rates for pilot studies of NIPD, financial implications and educational and counselling resources. A determination of the preferred model is therefore inappropriate at this stage and we do not adopt a preferred model in this paper, although we briefly discuss policy implications in section “Implications for Policy”.
 
5
Further analysis and comparison of these terms has been undertaken elsewhere [7].
 
6
Decision-making on the basis of probability, or uncertainty, can be problematic for different reasons. Making a decision on the basis of uncertain information involves a risk analysis. It is possible, for example, that a woman could terminate her pregnancy on the basis of the probability that the fetus carries a certain genetic condition, only to find that in fact the fetus did not have that condition. Indeed, avoidance of such problems of uncertainty forms part of the appeal of NIPD.
 
7
This will, of course, depend on the clinical utility and validity of this test, and women’s acceptance of its reliability.
 
Literature
1.
go back to reference Benn, P. A., & Chapman, A. R. (2009). Practical and ethical considerations of noninvasive prenatal diagnosis. Journal of the American Medical Association, 301(20), 2154–2156.PubMedCrossRef Benn, P. A., & Chapman, A. R. (2009). Practical and ethical considerations of noninvasive prenatal diagnosis. Journal of the American Medical Association, 301(20), 2154–2156.PubMedCrossRef
2.
go back to reference de Jong, A., Dondorp, W. J., de Die-Smulders, C. E. M., Frints, S. G, M. & de Wert, G. M. W. R. (2009) Non-invasive prenatal testing: Ethical issues explored. European Journal of Human Genetics advance online publication 2 December 2009; doi:10.1038/ejhg.2009.203. de Jong, A., Dondorp, W. J., de Die-Smulders, C. E. M., Frints, S. G, M. & de Wert, G. M. W. R. (2009) Non-invasive prenatal testing: Ethical issues explored. European Journal of Human Genetics advance online publication 2 December 2009; doi:10.​1038/​ejhg.​2009.​203.
3.
go back to reference Faden, R. R., & Beauchamp, T. L. (1986). A history and theory of informed consent. New York, Oxford: Oxford University Press. Faden, R. R., & Beauchamp, T. L. (1986). A history and theory of informed consent. New York, Oxford: Oxford University Press.
4.
go back to reference García, E., Timmermans, D. R. M., & van Leeuwen, E. (2009). Reconsidering prenatal screening: An empirical-ethical approach to understand moral dilemmas as a question of personal preference. Journal of Medical Ethics, 35, 410–414.PubMedCrossRef García, E., Timmermans, D. R. M., & van Leeuwen, E. (2009). Reconsidering prenatal screening: An empirical-ethical approach to understand moral dilemmas as a question of personal preference. Journal of Medical Ethics, 35, 410–414.PubMedCrossRef
5.
go back to reference Getz, L., & Kirkengen, A. (2003). Ultrasound screening in pregnancy: Advancing technology, soft markers for fetal chromosomal aberrations, and unacknowledged ethical dilemmas. Social Science and Medicine, 56, 2045–2057.PubMedCrossRef Getz, L., & Kirkengen, A. (2003). Ultrasound screening in pregnancy: Advancing technology, soft markers for fetal chromosomal aberrations, and unacknowledged ethical dilemmas. Social Science and Medicine, 56, 2045–2057.PubMedCrossRef
6.
go back to reference Hahn, S., & Chitty, L. S. (2008). Noninvasive prenatal diagnosis: Current practice and future perspectives. Current Opinion in Obstetrics and Gynecology, 20(2), 146–151.PubMedCrossRef Hahn, S., & Chitty, L. S. (2008). Noninvasive prenatal diagnosis: Current practice and future perspectives. Current Opinion in Obstetrics and Gynecology, 20(2), 146–151.PubMedCrossRef
7.
go back to reference Marteau, T. M. (2009). Informed choice: A construct in search of a name. Edwards, A. & Elwyn, G. shared decision-making in health care: Achieving evidence-based patient choice. Oxford: Oxford University Press (Chap. 13). Marteau, T. M. (2009). Informed choice: A construct in search of a name. Edwards, A. & Elwyn, G. shared decision-making in health care: Achieving evidence-based patient choice. Oxford: Oxford University Press (Chap. 13).
8.
go back to reference Marteau, T. M., Dormandy, E., & Michie, S. (2001). A measure of informed choice. Health Expectations, 4(2), 99–108.PubMedCrossRef Marteau, T. M., Dormandy, E., & Michie, S. (2001). A measure of informed choice. Health Expectations, 4(2), 99–108.PubMedCrossRef
10.
go back to reference Newson, A. J. (2008). Ethical aspects arising from non-invasive fetal diagnosis. Seminars in Fetal Neonatal Medicine, 13(2), 103–108.PubMedCrossRef Newson, A. J. (2008). Ethical aspects arising from non-invasive fetal diagnosis. Seminars in Fetal Neonatal Medicine, 13(2), 103–108.PubMedCrossRef
11.
go back to reference O’Neill, O. (2002). Autonomy and trust in bioethics. Cambridge: Cambridge University Press.CrossRef O’Neill, O. (2002). Autonomy and trust in bioethics. Cambridge: Cambridge University Press.CrossRef
12.
13.
go back to reference Press, N., & Browner, C. H. (1995). Risk, autonomy, and responsibility: Informed consent for prenatal testing. Hastings Center Report, 25(3), S9–S12.CrossRef Press, N., & Browner, C. H. (1995). Risk, autonomy, and responsibility: Informed consent for prenatal testing. Hastings Center Report, 25(3), S9–S12.CrossRef
15.
go back to reference Schmitz, D., Netzer, C., & Henn, W. (2009). An offer you can’t refuse? Ethical implications of non-invasive prenatal diagnosis. Nature Reviews Genetics, 10, 515.PubMedCrossRef Schmitz, D., Netzer, C., & Henn, W. (2009). An offer you can’t refuse? Ethical implications of non-invasive prenatal diagnosis. Nature Reviews Genetics, 10, 515.PubMedCrossRef
16.
go back to reference Scully, J., Porz, R., & Rehmann-Sutter, C. (2007). You don’t make genetic test decisions from one day to the next—using time to preserve moral space. Bioethics, 2(14), 208–217.CrossRef Scully, J., Porz, R., & Rehmann-Sutter, C. (2007). You don’t make genetic test decisions from one day to the next—using time to preserve moral space. Bioethics, 2(14), 208–217.CrossRef
17.
go back to reference van den Heuvel, A., et al. (2010). Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An Experimental Study of Health Care Professionals. Patient Education and Counseling, 78(1), 24–28.PubMedCrossRef van den Heuvel, A., et al. (2010). Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An Experimental Study of Health Care Professionals. Patient Education and Counseling, 78(1), 24–28.PubMedCrossRef
18.
go back to reference Vassy, C. (2006). From a genetic innovation to mass health programmes: The diffusion of down’s syndrome prenatal screening and diagnostic techniques in France. Social Science and Medicine, 63, 2041–2051.PubMedCrossRef Vassy, C. (2006). From a genetic innovation to mass health programmes: The diffusion of down’s syndrome prenatal screening and diagnostic techniques in France. Social Science and Medicine, 63, 2041–2051.PubMedCrossRef
19.
go back to reference Wright, C. F., & Burton, H. (2009). The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Human Reproduction Update, 15(1), 139–151.PubMedCrossRef Wright, C. F., & Burton, H. (2009). The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Human Reproduction Update, 15(1), 139–151.PubMedCrossRef
20.
go back to reference Wright, C. F., & Chitty, L. S. (2009). Cell-free fetal DNA and RNA in maternal blood: Implications for safer antenatal testing. British Medical Journal, 339, b2451.PubMedCrossRef Wright, C. F., & Chitty, L. S. (2009). Cell-free fetal DNA and RNA in maternal blood: Implications for safer antenatal testing. British Medical Journal, 339, b2451.PubMedCrossRef
Metadata
Title
Should Non-Invasiveness Change Informed Consent Procedures for Prenatal Diagnosis?
Authors
Zuzana Deans
Ainsley J. Newson
Publication date
01-06-2011
Publisher
Springer US
Published in
Health Care Analysis / Issue 2/2011
Print ISSN: 1065-3058
Electronic ISSN: 1573-3394
DOI
https://doi.org/10.1007/s10728-010-0146-8

Other articles of this Issue 2/2011

Health Care Analysis 2/2011 Go to the issue